Table 1.
Baseline Characteristics of Patients With Chronic Kidney Disease Treated With Placebo or Cholecalciferol (Vitamin D3)a
| Placebo | Cholecalciferol | |
|---|---|---|
| Characteristics | (n = 10) | (n = 10) |
| Ethnicity, No. | ||
| African American | 7 | 6 |
| Nonhispanic white | 3 | 4 |
| Female, No. | 6 | 6 |
| Age, y | 59.5 (10.4) | 62.2 (11) |
| GFR, mL/min/1.73 m2 body surface area | 29.8 (13.6) | 33.3 (26.8) |
| Stage 4 kidney disease (GFR,15– 30 mL/min/1.73 m2 body surface area), No. |
5 | 3 |
| Stage 3 kidney disease (GFR, 31– 59 mL/min/1.73 m2 body surface area), No. |
5 | 7 |
| Serum albumin, g/dL | 3.7 (0.3) | 3.5 (0.3) |
| Hemoglobin, g/dL | 11.9 (0.9) | 12.0 (1.6) |
| Serum phosphorus, mg/dL | 3.9 (0.6) | 4.1 (0.6) |
| Calcium ×phosphorus product | 36.3 (7.6) | 39.3 (7.5) |
| Serum AST, U/L | 22.3 (5.4) | 24.2 (9.2) |
| Serum ALT, U/L | 18.2 (4.7) | 21.8 (8.8) |
| Participants taking daily multivitamin supplements, No. |
8 | 9 |
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; GFR, glomerular filtration rate.
a
Data are presented as mean (SD) unless otherwise indicated.